Project Grant R37CA291990
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded The Regents of the University of Colorado-Denver a Project Grant totaling $2.89 million under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a comprehensive, multidisciplinary investigation of cannabis use's impact on pain and recovery following total knee arthroplasty (TKA) surgery. The research, which commenced September 5, 2025, and extends through August 31, 2030,...
- Federal Project Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $429,162 Project Grant (CFDA 93.395, Cancer Treatment Research program) effective August 1, 2025 through July 31, 2027 to conduct a prospective feasibility study exploring the neuroprotective potential of cannabidiol (CBD) in preventing oxaliplatin-induced peripheral neuropathy in colorectal cancer patients. The research deliverables include: (1) evaluation of the feasibility and...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The University of Kentucky Research Foundation a $647,142 Project Grant on February 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct controlled research examining the impact of cannabis on opioid self-administration in individuals with opioid use disorder. The research will be completed by November 30, 2030, and will deliver fundamental public health data addressing a critical gap...
- Federal Grant Award Summary Washington State University received a $153,000 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) beginning June 15, 2025, and concluding May 31, 2027. The award supports a six-month longitudinal research study examining the relationship between naturalistic cannabis use and daily functioning in young adults with chronic pain using an innovative ecological momentary assessment burst...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded Albert Einstein College of Medicine a $199,584 Project Grant, effective March 15, 2026, through February 28, 2031, under the Drug Use and Addiction Research Programs (CFDA 93.279). Dr. Michele Buonora will conduct a five-year hybrid effectiveness-implementation study examining patient-controlled analgesia (PCA) for acute pain management in hospitalized individuals with opioid use disorder (POUD). The research will...
- Federal Grant Award Summary The Medical University of South Carolina received a $686,692 Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) beginning September 1, 2025, and concluding July 31, 2030. This award supports a prospective clinical trial investigating the potential benefits of cannabis use reduction as a harm reduction strategy for adults with cannabis use disorder (CUD). The research addresses a significant gap in...
- This $668,110 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund the development and acceptability testing of a technology-based intervention to reduce cannabis misuse among college students. The project aims to refine an existing intervention that provides information on cannabis products, marketing, laws, and risks to increase young adults' cannabis literacy. The research will involve focus groups with...
- Federal Grant Award Summary Oregon Health & Science University received a $791,990 Project Grant award effective June 15, 2025, from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a longitudinal mechanistic study examining reciprocal relationships between cannabis use, sleep, and hypothalamic-pituitary-adrenal (HPA) axis functioning. The three-year research initiative (completion date April 30, 2030) will enroll 60...
- Grant Award Summary Media REZ LLC (doing business as Daniel Greenberg & Associates) received a $404,295 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) awarded on September 8, 2025, with a completion date of August 31, 2026. The award funds the development of a patient-directed Virtual Reality (VR) intervention designed to provide non-pharmacologic management of chronic cancer pain. The project employs an iterative,...
- Federal Grant Award Summary Medstar Health Research Institute Inc. received a $403,383 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on June 1, 2025, with completion anticipated by May 31, 2027. The award supports the development and feasibility testing of a cognitive behavioral theory-assisted virtual reality (VR) therapeutic device prototype designed to address chronic cancer pain management. The project, conducted in...
IMPACT OF STATE CANNABIS LAWS ON CANCER PAIN MANAGEMENT AND OUTCOMES: A MIXED-METHODS STUDY - PROJECT SUMMARY/ABSTRACT MORE THAN ONE THIRD OF THE APPROXIMATELY 2 MILLION AMERICANS DIAGNOSED WITH CANCER EACH YEAR EXPERIENCE MODERATE TO SEVERE PAIN RELATED TO THEIR DISEASE AND/OR ITS TREATMENT. TO DATE, 38 STATES AND THE DISTRICT OF COLUMBIA HAVE ADOPTED MEDICAL CANNABIS LAWS, AND 24 HAVE SUBSEQUENTLY ADOPTED ADULT-USE (I.E., "RECREATIONAL") CANNABIS USE LAWS, THAT ENABLE PATIENTS WITH CANCER TO USE CANNABIS FOR PAIN MANAGEMENT. CLINICAL PRACTICE GUIDELINES DO NOT RECOMMEND THE USE OF CANNABIS TO MANAGE CANCER PAIN, CITING LIMITED AND MIXED EVIDENCE. INSTEAD, GUIDELINES CONTINUE TO EMPHASIZE OPIOID THERAPY AS A CORNERSTONE OF CANCER PAIN MANAGEMENT. THE STRENGTH OF SUCH CONSENSUS VARIES SOMEWHAT ACROSS CANCER CONTEXTS. CONSENSUS ON THE APPROPRIATENESS OF OPIOID THERAPY IS STRONGEST FOR PATIENTS WITH ADVANCED (I.E., INCURABLE) CANCER, ESPECIALLY THOSE WITH LIMITED LIFE EXPECTANCY. IT IS ALSO STRONG FOR PATIENTS UNDERGOING ACTIVE CANCER TREATMENT WITH CURATIVE INTENT. IN CONTRAST, GUIDELINES FOR CHRONIC PAIN MANAGEMENT AMONG CANCER SURVIVORS (I.E., THOSE WHO HAVE COMPLETED CURATIVE TREATMENT AND ARE IN REMISSION) REFLECT AN EMERGING EMPHASIS ON OPIOID-SPARING APPROACHES. REGARDLESS OF GUIDELINE RECOMMENDATIONS, MANY PATIENTS WITH CANCER PREFER TO LIMIT OR AVOID USING OPIOIDS. IN THIS CONTEXT AND BASED ON PRIOR STUDIES DOCUMENTING RATES OF CANNABIS USE EXCEEDING 25% AMONG PATIENTS WITH CANCER, CANNABIS LAWS COULD LEAD PATIENTS TO USE CANNABIS IN PLACE OF OPIOID THERAPY, WITH DOWNSTREAM EFFECTS THAT ARE UNKNOWN AND MAY DIFFER ACROSS CANCER CONTEXTS. THE OBJECTIVE OF THE PROPOSED STUDY IS TO ADDRESS EVIDENCE GAPS ABOUT THE EFFECTS OF STATE CANNABIS LAWS ON PAIN MANAGEMENT PRACTICES (E.G., RECEIPT OF OPIOID THERAPY) AND OUTCOMES (E.G., RECEIPT OF TREATMENT FOR OPIOID AND CANNABIS USE DISORDER; PATIENT-REPORTED PAIN) IN CANCER. WE WILL CONDUCT A QUASI-EXPERIMENTAL EVALUATION OF STATE CANNABIS LAWS USING A UNIQUE COMBINATION OF TWO EXISTING POPULATION-BASED DATA SOURCES (SEER-MEDICARE AND SEER-MHOS). WE WILL ALSO COLLECT AND ANALYZE SURVEY AND INTERVIEW DATA TO EXPLORE HOW STATE CANNABIS LAWS HAVE INFLUENCED CANCER PAIN MANAGEMENT FROM THE PERSPECTIVES OF CANCER CENTER LEADERS, PHYSICIANS, AND PATIENTS. TRIANGULATING RESULTS FROM OUR POLICY EVALUATION WITH INFORMATION ABOUT CANCER CENTER-LEVEL IMPLEMENTATION OF STATE CANNABIS LAWS, PHYSICIANS' PRACTICES FOR RECOMMENDING, AND PATIENTS' PRACTICES FOR USING CANNABIS FOR CANCER PAIN WILL STRENGTHEN THE VALIDITY OF OBSERVED POLICY EFFECTS. EACH YEAR, STATES CONSIDER, ENACT, AND/OR AMEND CANNABIS LAWS. TO INFORM THIS RAPIDLY EVOLVING POLICY CONTEXT, IT IS ESSENTIAL TO UNDERSTAND HOW THESE LAWS AFFECT PAIN MANAGEMENT FOR PATIENTS WITH CANCER AS ONE OF THE LARGEST GROUPS OF CONSUMERS OF THERAPEUTIC CANNABIS. OUR PROPOSED STUDY HAS SIGNIFICANT POTENTIAL TO IMPACT POLICY AND PRACTICE.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | ($448k) | 6/17/25 | ||
| Not listed | $448.3k | 6/17/25 | ||
| Not listed | $0 | 6/17/25 | ||
| Not listed | $527.9k | 6/6/25 | ||
| Not listed | $527.9k | 6/6/25 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
SUBK00023706S | Weill Medical College Of Cornell University | Project Grant R37CA291990 | $61.7k | 10/9/25 | |
SUBK00023705S | The Trustees Of The University Of Pennsylvania | Project Grant R37CA291990 | $38.9k | 9/16/25 | |
SUBK00025044S | The Ohio State University | Project Grant R37CA291990 | $36.5k | 9/11/25 | |
SUBK00023707S | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Project Grant R37CA291990 | $37.9k | 9/2/25 | |
SUBK00023702S | Duke University | Project Grant R37CA291990 | $59.9k | 9/2/25 |